Bond.az - Goldman Sachs initiated coverage on Hemab Therapeutics Holdings (NASDAQ:COAG) with a buy rating and a price target of $36.00. The stock currently trades at $25.89, representing roughly 39% upside to the analyst’s target, though shares have declined nearly 24% over the past six months.
The firm’s lead asset, sutacimig, is a bispecific antibody in Phase 1/2 studies as a prophylactic subcutaneous treatment for Glanzmann thrombasthenia and Factor VII deficiency. No subcutaneous prophylaxis is currently available for these conditions.
Sutacimig has shown up to 87% reduction in annualized treated bleed rates in Glanzmann thrombasthenia. Both disorders are genetic orphan diseases with approximately 1,000 patients each in the United States. Goldman Sachs models sutacimig achieving approximately $1.3 billion non-risk adjusted peak sales.
Hemab’s second asset, HMB-002, is a monovalent antibody being developed as subcutaneous prophylaxis for von Willebrand disease in a Phase 1/2 trial. Hemlibra achieved more than $5 billion in global revenues in 2025.
The company maintains a strong balance sheet with a current ratio of 18.03. Readouts in late 2026 and early 2027 for key trials are expected. In other recent news, Hemab completed its IPO on the Nasdaq, raising approximately $346.7 million.
